Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

BELLEVUE, WA, June 11 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today announced that the first patient has been treated in a Phase 1b clinical trial of PX-12 in patients with advanced metastatic cancer. PX-12 is a proprietary small molecule inhibitor of thioredoxin, a protein that regulates diverse molecular pathways that contribute to the growth, survival and drug resistance of many cancers.

The primary objective of the Phase 1b dose-escalation trial is to determine the safety and tolerability of a 72-hour continuous infusion of PX-12 given on the first three days of a 21-day cycle. Other objectives of the trial include an evaluation of the pharmacokinetics and pharmacodynamics of the prolonged infusion, together with identification of any anti-tumor activity. The trial is expected to enroll up to 28 patients at three centers in the United States.

About PX-12

PX-12 is a small molecule designed to inhibit thioredoxin-1. Increased levels of thioredoxin-1 have been noted in many types of cancer cells, including hepatoma, lung cancers, squamous cervical carcinoma, primary gastric cancers and colorectal carcinomas. Increased levels of thioredoxin-1 are associated with decreased sensitivity to a variety of common chemotherapy agents and may cause or contribute to drug resistance.

An initial Phase 1 trial of PX-12 in 38 patients with advanced metastatic cancer showed that PX-12 was well tolerated and produced a decrease in plasma concentrations of thioredoxin that was significantly correlated with increased patient survival. Fifteen of the 38 patients achieved stable disease of up to 322 days. Oncothyreon is also currently conducting a Phase 2 trial of PX-12 given as a 3-hour
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  In recognition of World Hemophilia ... hemophilia advocacy groups to illuminate more than 15 prominent landmarks ... Boston,s Zakim Bridge and Prudential Tower, ... Orleans, Mercedes-Benz Superdome and Denver,s ... the evening of April 17, and coincide with hemophilia community ...
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is ... newest office in Charlottetown , PEI.  ... Prince Edward Island ADAPT Council for the commercialization of ... forward to working with PEI ADAPT.  They have been ... more than a decade," explains Dave Smardon , ...
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... Jan. 5 RainDance Technologies, Inc., a,provider of innovative ... that it has been selected to share in the,first-ever ... Center (MLSC). , The MLSC ... years to Dr. David,Weitz, Mallinckrodt Professor of Physics and ...
... DEERFIELD, Ill. and SAN DIEGO, Jan. 5 ... HALO ) today,announced the start of a ... Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in ... (rHuPH20,Enhanze(TM) Technology) for the treatment of primary immunodeficiency ...
... Singapore investigators to coordinate 700 patient trial of ... of head and neck cancer,MISSISSAUGA, ON, Jan. 5 ... TSX:YM, AIM:YMBA), an oncology company that identifies, develops ... announced that the National Cancer Centre of Singapore ...
Cached Biology Technology:RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants 2RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants 3RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 2Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 3Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 5YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 2YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 3YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 4
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... how an enzyme repairs DNA. Enzymes called helicases ... Maria Spies, a University of Illinois biochemistry professor. ... machineries orchestrating DNA repair in the cell. she said. ... malfunctions in these enzymes. Spies laboratory undertook a ...
... Povich of the yellow jacket world. In his laboratory, ... family dynamics within a colony. Even though only one ... mates with several males, creating a complex family tree. ... described as one of the greatest achievements of evolution ...
... is available in French . , Imagine a ... of CO 2 the equivalent of 2.2 days ... measuring up to 100 metres in radius and several kilometres ... below the oceans surface. At first blush, this might ...
Cached Biology News:Researchers probe a DNA repair enzyme 2Research uncovers the social dynamics of yellow jackets 2Research uncovers the social dynamics of yellow jackets 3Research uncovers the social dynamics of yellow jackets 4Into the abyss: Deep-sixing carbon 2
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
Topoisomerase II...
Biology Products: